Piper Jaffray Companies restated their buy rating on shares of Zoetis (NYSE:ZTS) in a research note published on Thursday. They currently have a $86.00 target price on the stock.

A number of other research firms also recently commented on ZTS. Jefferies Group reissued a buy rating and set a $89.00 price objective on shares of Zoetis in a report on Tuesday, January 16th. Zacks Investment Research downgraded shares of Zoetis from a hold rating to a sell rating and set a $83.00 price objective on the stock. in a report on Saturday, January 13th. BMO Capital Markets boosted their price objective on shares of Zoetis to $78.00 and gave the stock a market perform rating in a report on Tuesday, January 9th. Cantor Fitzgerald set a $85.00 price objective on shares of Zoetis and gave the stock a buy rating in a report on Thursday, January 11th. Finally, Citigroup raised shares of Zoetis from a neutral rating to a buy rating and set a $85.00 price objective on the stock in a report on Thursday, January 4th. Two analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $73.72.

Shares of Zoetis (NYSE ZTS) opened at $76.62 on Thursday. The company has a market cap of $37,340.00, a PE ratio of 40.33, a P/E/G ratio of 1.83 and a beta of 1.06. Zoetis has a fifty-two week low of $52.00 and a fifty-two week high of $77.03. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.02. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The firm’s revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.52 earnings per share. analysts forecast that Zoetis will post 2.36 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be issued a $0.126 dividend. This represents a $0.50 annualized dividend and a dividend yield of 0.66%. The ex-dividend date of this dividend is Thursday, January 18th. This is an increase from Zoetis’s previous quarterly dividend of $0.11. Zoetis’s dividend payout ratio is 26.32%.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Zoetis by 16.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after purchasing an additional 230 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in shares of Zoetis in the third quarter valued at about $114,000. Harfst & Associates Inc. lifted its stake in shares of Zoetis by 16.1% during the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after buying an additional 260 shares during the period. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its stake in shares of Zoetis by 251.9% during the third quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after buying an additional 1,360 shares during the period. Finally, Shine Investment Advisory Services Inc. lifted its stake in shares of Zoetis by 86.5% during the third quarter. Shine Investment Advisory Services Inc. now owns 2,242 shares of the company’s stock valued at $143,000 after buying an additional 1,040 shares during the period. 93.14% of the stock is currently owned by institutional investors.

WARNING: “Piper Jaffray Companies Reiterates Buy Rating for Zoetis (ZTS)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2018/01/22/piper-jaffray-companies-reiterates-buy-rating-for-zoetis-zts.html.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.